<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055312</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-007</org_study_id>
    <nct_id>NCT03055312</nct_id>
  </id_info>
  <brief_title>Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer</brief_title>
  <acronym>SYSUCC-007</acronym>
  <official_title>A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatment of AR Positive Metastatic Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's&#xD;
      Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III,Multi-center,prospective,randomized clinical trials. The objective&#xD;
      compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's&#xD;
      Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast&#xD;
      cancer.Primary endpoint is 16-week clinical benefit rate (CBR).By centre randomized grouping&#xD;
      bicalutamide (experimental Group) or TPC (Control Group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">December 20, 2016</start_date>
  <completion_date type="Actual">November 15, 2020</completion_date>
  <primary_completion_date type="Actual">November 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate for 16 weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of patients with complete response, partial response and stable disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Metastatic Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TPC chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional chemotherapy(choose a):&#xD;
TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bicalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bicalutamide 150mg/day every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPC</intervention_name>
    <description>Conventional chemotherapy(choose a):&#xD;
TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.&#xD;
GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 &amp; days 8)every 3 weeks.&#xD;
GC:(Gemcitabine 1000mg/m2 on days 1 &amp; days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 &amp; days 8) every 3 weeks</description>
    <arm_group_label>TPC chemotherapy</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide 150 mg</intervention_name>
    <description>Bicalutamide 150mg/day,every 28 days</description>
    <arm_group_label>Bicalutamide</arm_group_label>
    <other_name>Bicalutamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years old, female&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1&#xD;
&#xD;
          -  Confirmed by pathology or organizing cytology AR positive(IHC：≧10%)triple negative&#xD;
             breast cancer&#xD;
&#xD;
          -  For the first time recurrence or newly diagnosed advanced breast cancer,Disease-free&#xD;
             survival time 12 months above&#xD;
&#xD;
          -  Measurable disease per RECIST version 1.1,or immeasurably lesions bone metastasis&#xD;
&#xD;
          -  After Recurrence has not received cancer treatment&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Signed and dated an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG score ≧2&#xD;
&#xD;
          -  Only brain metastasis or meningeal metastasis&#xD;
&#xD;
          -  Receiving other anti-tumor treatment&#xD;
&#xD;
          -  Heart,lung,liver,kidney,bone marrow,and other functions badness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-Yu Yuan, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University, Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

